SCHEMBL11934366

SCHEMBL11934366

CCN1CCCN(C)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PER2 O15055 5/20 0.42
BRD4 O60885 1/20 0.39
BRD2 P25440 1/20 0.39
CRY2 Q49AN0 2/20 0.38
INMT O95050 2/20 0.37
F2 P00734 1/20 0.35
ELANE P08246 1/20 0.35
CTSG P08311 1/20 0.35
CTRC Q99895 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
IDE P14735 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
PIK3CD O00329 1/20 0.32
GAA P10253 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL329639 0.86
SCHEMBL6365391 0.85 PER2 (0.46) PER2CRY2INMTF2ELANE
SCHEMBL13208691 0.84 PER2 (0.41) PER2BRD4BRD2CRY2KDM4E
SCHEMBL1446053 0.83 PER2 (0.40) PER2BRD4BRD2CRY2INMT
SCHEMBL19383610 0.82 PER2 (0.42) PER2BRD4BRD2CRY2
SCHEMBL13504054 0.81 PER2 (0.39) PER2BRD4BRD2CRY2KDM4E
SCHEMBL10416543 0.80 PER2 (0.42) PER2CRY2INMTF2ELANE
SCHEMBL1445993 0.80 PER2 (0.41) PER2BRD4BRD2CRY2PIK3CD
SCHEMBL1446202 0.80 PER2 (0.41) PER2BRD4BRD2CRY2PIK3CD
SCHEMBL1446205 0.78 PER2 (0.43) PER2BRD4BRD2CRY2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed
WO-2022221704-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER HOTSPOT THERAPEUTICS, INC. (US) 2022-10-20 WO disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 US disclosed
US-11078228-B2 Ectonucleotidase inhibitors and methods of use thereof CALITHERA BIOSCIENCES, INC. (US) 2021-08-03 US disclosed
US-10179793-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2019-01-15 US disclosed
US-9783527-B2 Indazole ureas and method of use ABBVIE INC. (US) 2017-10-10 US disclosed
US-20170145028-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC (US) 2017-05-25 US disclosed
WO-2017075056-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC (US) 2017-05-04 WO disclosed
US-8211932-B2 Organic compounds and their uses NOVARTIS AG (CH) 2012-07-03 US disclosed
US-7619094-B2 Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus SCHERING CORPORATION (US) 2009-11-17 US disclosed
US-7449447-B2 Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2008-11-11 US disclosed
US-7279444-B2 Substituted benzoylpyrazoles BAYER CROPSCIENCE GMBH (DE) 2007-10-09 US disclosed
US-7279444-B2 Substituted benzoylpyrazoles BAYER CROPSCIENCE GMBH (DE) 2007-10-09 US disclosed
US-20070185326-A1 antiinflammatory agents; antiarthritic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 US disclosed
US-20070185326-A1 antiinflammatory agents; antiarthritic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 US disclosed
EP-1263738-B1 SUBSTITUTED BENZOYLCYCLOHEXENONES BAYER CROPSCIENCE AG (DE) 2007-06-27 EP disclosed
EP-1790700-A1 Organic solvent based ink Composition TOYO INK MFG. CO., LTD. (JP) 2007-05-30 EP disclosed
US-20070093430-A1 Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus MERCK SHARP & DOHME CORP. 2007-04-26 US disclosed
US-7173057-B2 Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus SCHERING CORPORATION (US) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145028-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 PER2 4070/4885BRD4 1815/4885BRD2 3443/4885
US-10179793-B2 ACC inhibitors and uses thereof ACACA, ACACB, ACAT2 PER2 4070/4885BRD4 1815/4885BRD2 3443/4885
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL PER2 4559/4885BRD4 1745/4885BRD2 2215/4885
US-20070093430-A1 Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus PREP, PRSS1, P4HB PER2 1963/4885BRD4 1071/4885BRD2 2842/4885
US-11078228-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 PER2 3239/4885BRD4 2032/4885BRD2 2849/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL PER2 4559/4885BRD4 1745/4885BRD2 2215/4885
US-20070185326-A1 antiinflammatory agents; antiarthritic agents MAPK1, CHUK, MAPK3 PER2 2607/4885BRD4 304/4885BRD2 543/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV PER2 3696/4885BRD4 3186/4885BRD2 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.